Open AccessEvaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA
Author(s) -
Tilak Sundaresan,
Taronish D. Dubash,
Zongli Zheng,
Aditya Bardia,
Ben S. Wittner,
Nicola Aceto,
Erin J. Silva,
Douglas B. Fox,
Matthew Liebers,
Ravi Kapur,
John Iafrate,
Mehmet Toner,
Shyamala Maheswaran,
Daniel A. Haber
Publication year - 2021
Publication title -
breast cancer research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 154
eISSN - 1573-7217
pISSN - 0167-6806
DOI - 10.1007/s10549-021-06270-z
Subject(s) - estrogen receptor alpha , digital polymerase chain reaction , breast cancer , metastatic breast cancer , circulating tumor cell , estrogen receptor , medicine , oncology , cancer research , biology , genotyping , cancer , cold pcr , mutation , metastasis , genotype , point mutation , genetics , polymerase chain reaction , gene
Therapeutic efficacy of hormonal therapies to target estrogen receptor (ER)-positive breast cancer is limited by the acquisition of ligand-independent ESR1 mutations, which confer treatment resistance to aromatase inhibitors (AIs). Monitoring for the emergence of such mutations may enable individualized therapy. We thus assessed CTC- and ctDNA-based detection of ESR1 mutations with the aim of evaluating non-invasive approaches for the determination of endocrine resistance.